DeepMed Research

PACIRA PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: EXPAREL

First Posted Date: 2014-08-06

Last Posted Date: 2021-07-06

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 60

Registration Number: NCT02210247

Locations: 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

Phase 4

Completed

Conditions: Pain

Interventions: Drug: EXPAREL

First Posted Date: 2014-07-24

Last Posted Date: 2021-03-08

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 12

Registration Number: NCT02199574

Locations: 🇺🇸
Memorial Hermann - Memorial City Medical Center, Houston, Texas, United States
🇺🇸
Memorial Village Surgery Center, Houston, Texas, United States

Pain Control in Bariatric Patients: EXPAREL(R) vs. the On-Q(R) Pain Ball

Phase 4

Completed

Conditions: Obesity

Interventions: Drug: EXPAREL
Drug: On-Q Pain Ball

First Posted Date: 2014-05-20

Last Posted Date: 2014-05-22

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 101

Registration Number: NCT02142829

Locations: 🇺🇸
Bariatric Medical Institute of Texas, San Antonio, Texas, United States

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

Phase 2

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Drug: FX006 32 mg
Drug: FX006 16 mg
Drug: Placebo

First Posted Date: 2014-04-17

Last Posted Date: 2024-01-24

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 310

Registration Number: NCT02116972

A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy

Phase 4

Terminated

Conditions: Bowel Obstruction

Interventions: Drug: IV morphine sulfate or Sponsor-approved equivalent
Drug: EXPAREL

First Posted Date: 2014-02-10

Last Posted Date: 2014-05-14

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 122

Registration Number: NCT02058290

Locations: 🇺🇸
Methodist Hospital, Houston, Texas, United States
🇺🇸
University of Miami, Dept. Anesthesiology, Miami, Florida, United States
🇺🇸
Tampa General Hospital, Tampa, Florida, United States

and more 3 locations

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

Phase 2

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Drug: FX006 40 mg
Drug: FX006 10 mg
Drug: TCA IR 40 mg

First Posted Date: 2013-12-06

Last Posted Date: 2024-01-24

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 50

Registration Number: NCT02003365

Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles

Completed

Conditions: Wrinkles

Interventions: Device: Cryotherapy for the utilization of wrinkle reduction (iovera)

First Posted Date: 2013-11-15

Last Posted Date: 2015-03-24

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 47

Registration Number: NCT01984619

Locations: 🇺🇸
The Aesthetics Research Center, Redwood City, California, United States

Effectiveness and Safety Study of the Iovera Device for the Temporary Reduction in the Appearance of Forehead Wrinkles

Not Applicable

Completed

Conditions: Forehead Wrinkles

Interventions: Device: iovera

First Posted Date: 2013-09-25

Last Posted Date: 2015-03-24

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 85

Registration Number: NCT01950065

Locations: 🇺🇸
Nashville Center for Laser and Facial Surgery, Nashville, Tennessee, United States
🇺🇸
Laser & Skin Surgery Center of NY, New York, New York, United States
🇺🇸
DeNova Research, Chicago, Illinois, United States

and more 3 locations

EXPAREL Administered Into the TAP for Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy

Phase 4

Terminated

Conditions: Postoperative Pain

Interventions: Drug: EXPAREL

First Posted Date: 2013-08-09

Last Posted Date: 2021-03-02

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 1

Registration Number: NCT01919606

EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries

Phase 4

Terminated

Conditions: Pain

Interventions: Drug: Placebo
Drug: EXPAREL

First Posted Date: 2013-08-08

Last Posted Date: 2021-07-02

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 67

Registration Number: NCT01919190

Locations: 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Duke University, Durham, North Carolina, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy